Vaccination in human solid tumors: Recent progress in the clinical arena

Giorgio Parmiani; Carolina Cimminiello; Cristina Maccalli; Vincenzo Russo

doi:10.1007/978-3-662-46410-6_2

Vaccination in human solid tumors: Recent progress in the clinical arena

Giorgio Parmiani, Carolina Cimminiello, Cristina Maccalli, Vincenzo Russo

IRCCS Ospedale San Raffaele

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Studies in animal models showed that antitumor immune response can be induced by a variety of cancer vaccines. This may also occur in the clinic, but the immune response in vaccinated cancer patients was rarely associated with a significant clinical response. This chapter will discuss (a) the crucial issue of the most appropriate tumor antigens (self vs. mutated) to be used for vaccination in human solid tumors; (b) the different factors that may impair antitumor immune response; (c) the reasons for the last, successful wave of vaccination trials; and (d) the role of combined vaccination and immunomodulation in the treatment of solid tumors.

Original language	English
Title of host publication	Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors
Publisher	Springer Berlin Heidelberg
Pages	41-46
Number of pages	6
ISBN (Print)	9783662464106, 9783662464090
DOIs	https://doi.org/10.1007/978-3-662-46410-6_2
Publication status	Published - Jan 1 2015

Keywords

Progression
Solid tumors
Vaccination

ASJC Scopus subject areas

Medicine(all)
Immunology and Microbiology(all)

Access to Document

10.1007/978-3-662-46410-6_2

Fingerprint Dive into the research topics of 'Vaccination in human solid tumors: Recent progress in the clinical arena'. Together they form a unique fingerprint.

Cite this

@inbook{6e67fd682119430d8b733547672d1db8,

title = "Vaccination in human solid tumors: Recent progress in the clinical arena",

abstract = "Studies in animal models showed that antitumor immune response can be induced by a variety of cancer vaccines. This may also occur in the clinic, but the immune response in vaccinated cancer patients was rarely associated with a significant clinical response. This chapter will discuss (a) the crucial issue of the most appropriate tumor antigens (self vs. mutated) to be used for vaccination in human solid tumors; (b) the different factors that may impair antitumor immune response; (c) the reasons for the last, successful wave of vaccination trials; and (d) the role of combined vaccination and immunomodulation in the treatment of solid tumors.",

keywords = "Progression, Solid tumors, Vaccination",

author = "Giorgio Parmiani and Carolina Cimminiello and Cristina Maccalli and Vincenzo Russo",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-3-662-46410-6_2",

language = "English",

isbn = "9783662464106",

pages = "41--46",

booktitle = "Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors",

publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Vaccination in human solid tumors

T2 - Recent progress in the clinical arena

AU - Parmiani, Giorgio

AU - Cimminiello, Carolina

AU - Maccalli, Cristina

AU - Russo, Vincenzo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Studies in animal models showed that antitumor immune response can be induced by a variety of cancer vaccines. This may also occur in the clinic, but the immune response in vaccinated cancer patients was rarely associated with a significant clinical response. This chapter will discuss (a) the crucial issue of the most appropriate tumor antigens (self vs. mutated) to be used for vaccination in human solid tumors; (b) the different factors that may impair antitumor immune response; (c) the reasons for the last, successful wave of vaccination trials; and (d) the role of combined vaccination and immunomodulation in the treatment of solid tumors.

AB - Studies in animal models showed that antitumor immune response can be induced by a variety of cancer vaccines. This may also occur in the clinic, but the immune response in vaccinated cancer patients was rarely associated with a significant clinical response. This chapter will discuss (a) the crucial issue of the most appropriate tumor antigens (self vs. mutated) to be used for vaccination in human solid tumors; (b) the different factors that may impair antitumor immune response; (c) the reasons for the last, successful wave of vaccination trials; and (d) the role of combined vaccination and immunomodulation in the treatment of solid tumors.

KW - Progression

KW - Solid tumors

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=84943408386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943408386&partnerID=8YFLogxK

U2 - 10.1007/978-3-662-46410-6_2

DO - 10.1007/978-3-662-46410-6_2

M3 - Chapter

AN - SCOPUS:84943408386

SN - 9783662464106

SN - 9783662464090

SP - 41

EP - 46

BT - Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors

PB - Springer Berlin Heidelberg

ER -